FR13C0009I2 - Peptide de suppression de l'appetit, ses compositions et son utilisation - Google Patents

Peptide de suppression de l'appetit, ses compositions et son utilisation

Info

Publication number
FR13C0009I2
FR13C0009I2 FR13C0009C FR13C0009C FR13C0009I2 FR 13C0009 I2 FR13C0009 I2 FR 13C0009I2 FR 13C0009 C FR13C0009 C FR 13C0009C FR 13C0009 C FR13C0009 C FR 13C0009C FR 13C0009 I2 FR13C0009 I2 FR 13C0009I2
Authority
FR
France
Prior art keywords
peptide
compositions
appetite suppression
appetite
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0009C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of FR13C0009I1 publication Critical patent/FR13C0009I1/fr
Application granted granted Critical
Publication of FR13C0009I2 publication Critical patent/FR13C0009I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR13C0009C 1996-03-01 2013-02-12 Peptide de suppression de l'appetit, ses compositions et son utilisation Active FR13C0009I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01
EP97905000A EP0891378B1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP01122701A EP1231218B1 (en) 1996-03-01 1997-02-27 An appetite-suppressing peptide, its compositions and use

Publications (2)

Publication Number Publication Date
FR13C0009I1 FR13C0009I1 (enExample) 2013-03-22
FR13C0009I2 true FR13C0009I2 (fr) 2013-08-16

Family

ID=26063575

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0009C Active FR13C0009I2 (fr) 1996-03-01 2013-02-12 Peptide de suppression de l'appetit, ses compositions et son utilisation

Country Status (22)

Country Link
EP (4) EP1231218B1 (enExample)
JP (1) JP4064460B2 (enExample)
KR (1) KR100611130B1 (enExample)
CN (1) CN1112367C (enExample)
AT (3) ATE395359T1 (enExample)
AU (1) AU710818B2 (enExample)
BR (1) BR9707807A (enExample)
CA (1) CA2246733C (enExample)
CY (2) CY2619B2 (enExample)
CZ (1) CZ297338B6 (enExample)
DE (3) DE69717092T2 (enExample)
DK (2) DK0891378T3 (enExample)
ES (3) ES2306685T3 (enExample)
FR (1) FR13C0009I2 (enExample)
HU (1) HU229234B1 (enExample)
IL (1) IL125805A0 (enExample)
NO (2) NO323043B1 (enExample)
PL (1) PL187095B1 (enExample)
PT (1) PT1975177E (enExample)
RU (1) RU2197261C2 (enExample)
UA (1) UA70283C2 (enExample)
WO (1) WO1997031943A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
PL187095B1 (pl) * 1996-03-01 2004-05-31 Novo Nordisk As Peptyd, kompozycja farmaceutyczna zawierająca peptyd, zastosowanie peptydu oraz zastosowanie frakcji HPLC ekstraktu nowotworu glukagonoma
BRPI9708566B8 (pt) 1996-04-12 2022-01-18 Ontario Inc 1149336 análogo de glp-2 de mamífero, e, composição farmacêutica.
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE366584T1 (de) * 1996-11-12 2007-08-15 Novo Nordisk As Verwendung von glp-1 peptiden
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
DE59811840D1 (de) * 1997-09-12 2004-09-23 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1056774A1 (en) * 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP1970072A1 (en) 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
CA2430934C (en) 2000-12-01 2011-06-21 Takeda Chemical Industries, Ltd. A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
RU2385879C2 (ru) 2004-01-21 2010-04-10 Ново Нордиск Хелс Кеа Аг Способ конъюгации пептидов, опосредованной трансглутаминазой
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
SI2409707T1 (sl) 2004-04-15 2015-07-31 Alkermes Pharma Ireland Limited Naprava s podaljšanim sproščanjem na osnovi polimerov
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
CN1950078A (zh) 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EA014184B1 (ru) 2005-05-04 2010-10-29 Зеаланд Фарма А/С Аналоги глюкагонподобного пептида-2 (glp-2)
DK1767545T3 (da) 2005-09-22 2010-03-15 Biocompatibles Uk Ltd GLP-1 (Glucagon-lignende peptid-1)-fusionspolypeptider med forøget peptidaseresistens
ATE444741T1 (de) 2006-05-10 2009-10-15 Biocompatibles Uk Ltd Glp-1 peptide enthaltende kugelförmige mikrokapseln, deren produktion und deren verwendung
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US8642727B2 (en) 2006-11-08 2014-02-04 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
JP5351884B2 (ja) 2007-04-23 2013-11-27 インターシア セラピューティクス，インコーポレイティド インスリン分泌促進性ペプチドの懸濁製剤及び使用
JP2010536717A (ja) * 2007-08-16 2010-12-02 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TR201802689T4 (tr) 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
SG11201810102SA (en) 2016-05-16 2018-12-28 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
ES2979184T3 (es) 2016-12-09 2024-09-24 Zealand Pharma As Agonistas duales de glp-1/glp-2 acilados
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
KR102754148B1 (ko) 2017-06-16 2025-01-15 질랜드 파마 에이/에스 글루카곤-유사-펩티드-2 (glp-2) 유사체의 투여를 위한 용량요법
WO2020223761A1 (en) * 2019-05-06 2020-11-12 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
UA41863C2 (uk) 1985-10-25 2001-10-15 Займодженетікс Інк. Спосіб одержання гетерологічного поліпептиду в еукаріотичних мікроорганізмах
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
ATE170557T1 (de) 1987-07-24 1998-09-15 Chiron Corp Züchtung von insektenzellen mit airlift-reaktoren
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
PL187095B1 (pl) * 1996-03-01 2004-05-31 Novo Nordisk As Peptyd, kompozycja farmaceutyczna zawierająca peptyd, zastosowanie peptydu oraz zastosowanie frakcji HPLC ekstraktu nowotworu glukagonoma

Also Published As

Publication number Publication date
HUP9902670A3 (en) 2000-02-28
PT1975177E (pt) 2011-07-26
ATE395359T1 (de) 2008-05-15
NO984005D0 (no) 1998-08-31
EP2295453A2 (en) 2011-03-16
WO1997031943A1 (en) 1997-09-04
CY2013008I2 (el) 2015-08-05
NO323043B1 (no) 2006-12-27
CZ273698A3 (cs) 1998-12-16
PL328732A1 (en) 1999-02-15
KR19990087439A (ko) 1999-12-27
NO984005L (no) 1998-08-31
DK0891378T3 (da) 2003-01-06
IL125805A0 (en) 1999-04-11
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
NO2013006I2 (enExample) 2013-03-12
DE69738695D1 (de) 2008-06-26
EP1231218B1 (en) 2008-05-14
DE69717092D1 (de) 2002-12-19
CN1215405A (zh) 1999-04-28
FR13C0009I1 (enExample) 2013-03-22
CA2246733C (en) 2010-07-20
ES2364705T3 (es) 2011-09-12
HU229234B1 (en) 2013-09-30
AU710818B2 (en) 1999-09-30
CY2619B2 (enExample) 2013-03-13
CA2246733A1 (en) 1997-09-04
CN1112367C (zh) 2003-06-25
DE69740176D1 (de) 2011-05-26
KR100611130B1 (ko) 2006-11-30
DE69717092T2 (de) 2003-07-24
EP1231218A2 (en) 2002-08-14
JP2000505460A (ja) 2000-05-09
BR9707807A (pt) 1999-07-27
ES2187756T3 (es) 2003-06-16
ES2306685T3 (es) 2008-11-16
EP1975177B1 (en) 2011-04-13
AU1871597A (en) 1997-09-16
CZ297338B6 (cs) 2006-11-15
CY2013008I1 (el) 2015-08-05
RU2197261C2 (ru) 2003-01-27
JP4064460B2 (ja) 2008-03-19
UA70283C2 (en) 2004-10-15
EP2295453A3 (en) 2011-03-30
DK1975177T3 (da) 2011-07-25
EP0891378A1 (en) 1999-01-20
ATE227737T1 (de) 2002-11-15
PL187095B1 (pl) 2004-05-31
EP0891378B1 (en) 2002-11-13
NO2013006I1 (no) 2013-04-02
EP1975177A1 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
FR13C0009I2 (fr) Peptide de suppression de l'appetit, ses compositions et son utilisation
NO20006194L (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
ATE366584T1 (de) Verwendung von glp-1 peptiden
DK0966297T4 (da) Regulering af gastrointestinal motilitet
NO992557L (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
ATE303438T1 (de) Menschlicher cysteinyl leukotrien rezeptor 2 (cyslt2)
ATE305478T1 (de) Topoisomerase-ii inhibitoren
GB9614191D0 (en) Oxadiazole benzenesulfonamides as selectives B3 agonists for the treatment of diabetes and obesity
TH26711A (th) " สิ่งที่คล้ายกันของปัจจัยหลั่งฮอโมนของการเจริญเติบโต "
MX9601655A (es) Proteinas (ob) obesas recombinantes.